The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer

Aim To determine whether the measurement of tissue mRNA levels of AMACR and survivin has a role in distinguishing prostate cancer (PCa) from benign lesions and high risk from low-risk PCa in men with suspected PCa. Methods TRUS prostate biopsies from 170 patients with suspected PCa were used to meas...

Full description

Saved in:
Bibliographic Details
Published in:International urology and nephrology 2012-12, Vol.44 (6), p.1681-1689
Main Authors: Al-Maghrebi, May, Kehinde, Elijah O., Anim, Jehoram T., Sheikh, Mehraj
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biopsy
Humans
Inhibitor of Apoptosis Proteins - genetics
Male
Medicine
Medicine & Public Health
Middle Aged
Nephrology
Prospective Studies
Prostate - chemistry
Prostate - pathology
Prostatic Neoplasms - chemistry
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Racemases and Epimerases - genetics
Risk Assessment - methods
RNA, Messenger - analysis
Urology
Urology - Original Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To determine whether the measurement of tissue mRNA levels of AMACR and survivin has a role in distinguishing prostate cancer (PCa) from benign lesions and high risk from low-risk PCa in men with suspected PCa. Methods TRUS prostate biopsies from 170 patients with suspected PCa were used to measure the mRNA levels of AMACR and survivin using semi-quantitative RT-PCR technique. The diagnosis, staging and risk stratification of PCa was based on established clinical criteria. The ability of tissue mRNA levels to distinguish benign from malignant prostate and high- and low-risk PCa was assessed. The diagnostic value for the two genes was evaluated by calculating their individual and combined sensitivity and specificity, which were compared with that of PSA. Results Histological examination showed 90/170 (53 %) of patients had benign prostate pathology, while 80/170 (47 %) had PCa. Tissue mRNA levels of both AMACR and survivin were able to distinguish benign from PCa biopsies ( p  
ISSN:0301-1623
1573-2584
DOI:10.1007/s11255-012-0220-2